Toronto, August 1, 2023–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or “companyA clinical-stage biopharmaceutical company revolutionizing mental health care by developing new and innovative psychedelic-based treatment options today announced the price of its previously announced night market public shares (“”).RecruitmentOf our total number of 24,264,706 units,unit“) The price per unit is USD 0.34 and the total revenue is USD 8,250,000.
Each unit consists of one common share of the capital of the Company (“common stock“) and one common stock purchase warrant (each entire common stock purchase warrant, “warrantEach warrant is exercisable to acquire one common share at a price of $0.40 per common share for a period of 60 months.
Cantor Fitzgerald & Co. is acting as sole bookkeeper for this offering. AGP/Alliance Global Partners is the lead manager for this service.
The offering is expected to close on or about August 4, 2023, or such other date as can be agreed upon by Cantor Fitzgerald & Company and the Company, and completion of the offering is subject to market and other customary conditions. (including market approval). Neo Exchange Inc. currently operates as Cboe Canada (“exchange“).
The Company intends to use the net proceeds from the offering to advance the Company's CYB003 and CYB004 programs and for general corporate and working capital purposes.
The Units will be offered in each province of Canada, except Quebec, and the United States pursuant to a prospectus supplement (“”).Supplement to the prospectus“) Our Short Form Base Prospectus dated July 5, 2021 (“Basic shelf prospectusA prospectus supplement is also filed with the U.S. Securities and Exchange Commission (“SEC“) as part of a registration statement on Form F-10 declared effective by the SEC on October 8, 2021 pursuant to the multijurisdictional disclosure system established between Canada and the United States. Before making an investment decision, prospective investors should consult the basic shelf prospectus and the Company's SEDAR profile available at www.sedar.com and the Company's EDGAR profile available at www.sec.gov. You should read the Base Shelf Prospectus and the documents incorporated by reference therein, including marketing materials.The Prospectus Supplement and the Base Shelf Prospectus are available from Cantor Fitzgerald & Co. (attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022) or by email at prospectus@cantor.com.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. .
About Cybin
Cybin is a clinical-stage company with a mission to develop safe and effective psychedelic-based treatments to address the significant unmet need for new and innovative treatments for people suffering from mental health conditions. is a biopharmaceutical company.
Cybin's goal to revolutionize mental health care is through a unique drug discovery platform, innovative drug delivery systems, world-class partners and internationally recognized science to advance new formulation approaches and treatment regimens. Supported by a network of people. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, as well as psychedelic compounds. The company has a research pipeline currently in research and development.
Headquartered in Canada, Cybin was founded in 2019 and has operations in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Cautionary statements and forward-looking statements
Certain statements in this press release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (collectively, “forward-looking statements”). All statements other than statements of historical fact contained in this press release. This includes, but is not limited to, statements regarding Cybin's future, strategies, plans, objectives, goals and objectives, and any statements that appear before, after, or contain the word “believe”. Not limited. , “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “will”, “anticipate”, “estimate” Words such as “anticipate'', “anticipate'', “project'', “seek'', “should'' or similar expressions or the negative thereof are forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the forward-looking statements in this news release regarding the expected closing of the offering, the use of the offering proceeds, the receipt of applicable regulatory approvals, including exchange approvals, and the Company's ability to address new and innovative needs. Contains description. Treatment options for people suffering from mental health conditions.
These forward-looking statements are based on the reasonable assumptions and estimates of the Company's management at the time such statements are made. Forward-looking statements involve known and unknown risks, uncertainties and the possibility that our actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or expressed. Actual future results may differ materially because of certain other factors. This is implied by such forward-looking statements. Such factors include, among others: changes in general macroeconomic conditions; Securities market fluctuations. Expectations regarding the size of the psychedelic market. our ability to successfully achieve our business objectives; Growth plan. political, social and environmental uncertainties; relationships with our employees; the existence of laws and regulations that may impose restrictions on the markets in which we operate; and as described in our management's discussion and analysis for the year ended March 31, 2023, in our Annual Information Form for the year ended March 31, 2023, and in our Listing Statement dated November 9, 2020. risk factors. See the SEC on Company Profile at www.sedar.com and his EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based on what the Company's management believes, or believes at the time, to be reasonable assumptions, the Company does not believe that actual results will reflect the forward-looking statements contained in this news release. Shareholders cannot be assured that the results will be consistent with such forward-looking statements. Because other factors may cause results not to be as anticipated, estimated, or intended. Readers should not place undue reliance on forward-looking statements or information contained in this news release. We undertake no obligation to update forward-looking statements regarding beliefs, opinions, projections or other factors should they change, except as required by law.
Cybin makes no medical, therapeutic, or health benefit claims for the products it suggests. The U.S. Food and Drug Administration, Health Canada, or any other similar regulatory authority has not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives, or other psychedelic compounds. The effectiveness of such products has not been confirmed by approved research. There is no guarantee that any disease or condition will be diagnosed, treated, cured, or prevented by the use of psilocybin, psychedelic tryptamine, tryptamine derivatives, or other psychedelic compounds. Rigorous scientific research and clinical trials are required. Cybin has not conducted clinical trials regarding the use of the proposed product. References to the quality, consistency, efficacy, or safety of potential products do not imply that Cybin has verified them in clinical trials or that Cybin has completed such trials. If Cybin is unable to obtain the necessary approvals or studies to commercialize its business, Cybin's results of operations and operations could be materially adversely affected.
Neither Neo Exchange Inc. nor NYSE American LLC Stock Exchange has approved or disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy of the contents of this news release.
View source version on businesswire.com. https://www.businesswire.com/news/home/20230801356442/ja/
contact address
Investor and Media Contact:
Gabriel Fael
chief legal officer
Cybin Co., Ltd.
1-866-292-4601
irteam@cybin.com – or – media@cybin.com
